Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Bad
|
New words:
Adimab, AlmataBio, baseline, BioCapital, call, China, Compelling, correlated, cutoff, DCR, devoted, dissolved, enable, fee, FL, Francisco, frequent, Gastrointestinal, Gilead, GITR, group, half, highest, Hong, improved, incidence, institutional, Israel, junction, Kong, Laurion, likelihood, LP, LPTX, Macau, Macrocure, mature, microsatellite, milestone, modulated, MSS, NovaRock, OS, partnership, pathway, people, Petach, PFS, plasma, platform, PR, pre, Preliminary, PRs, quarter, RECIST, remote, Republic, Rock, royalty, Samsara, San, SD, SDs, select, sell, shown, SOC, stable, strategic, subgroup, subpopulation, symbol, Symposium, Taiwan, technology, territory, Tikva, unaudited, underwriting, Wnt, young
Removed:
cliff, deferred, demonstrated, earlier, expired, GEA, nonemployee, nonqualified, opportunity, Restricted, September, settled, unregistered, whichever, xxi
Financial report summary
?Competition
Pfizer • AMGEN • Incyte • Astrazeneca • Novartis • Ngm Biopharmaceuticals • Checkpoint Therapeutics • Elevation OncologyManagement Discussion
- Research and development expenses were $11.3 million for the three months ended March 31, 2024, compared to $38.9 million for the three months ended March 31, 2023. The decrease of $27.6 million in R&D expenses during the three months ended March 31, 2024 as compared to the same period in 2023, was primarily due to $29.6 million of in-process research and development (“IPR&D”) acquired in the Flame merger which we expensed during the three months ended March 31, 2023. In addition, there was a decrease of $0.4 million in manufacturing costs related to clinical trial material and manufacturing campaigns and a decrease of $0.1 million in consulting fees associated with research and development activities. These decreases were partially offset by an increase of $2.0 million in clinical trial costs and an increase of $0.5 million in payroll and other related expenses due to an increase in headcount of our R&D full-time employees.